Evidence map›Paper›PMID 29505773›Full record

ArticleAmerican journal of obstetrics and gynecology2018

Impact of contraceptive initiation on vaginal microbiota.

Sharon L Achilles, Michele N Austin, Leslie A Meyn, Felix Mhlanga, Zvavahera M Chirenje, Sharon L Hillier

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in American journal of obstetrics and gynecology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 81 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 5 pooled it
9.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 5 syntheses or guidelines pooled it, 127 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Sexually Transmitted Infections Treatment Guidelines, 2021.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2021
    Guideline
  5. The Effect of Exogenous Sex Steroids on the Vaginal Microbiota: A Systematic Review.Frontiers in cellular and infection microbiology · 2021
    Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Genital inflammatory status and the innate immune response to contraceptive initiation.American journal of reproductive immunology (New York, N.Y. : 1989) · 2022
    Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Microbiome and chronic pelvic pain in women: a mini-review.Human reproduction (Oxford, England) · 2026
    Review
  17. Article
  18. Review
  19. Review
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Sharon L AchillesDepartment of Obstetrics, Gynecology, and Reproductive Sciences and Center for Family Planning Research, University of Pittsburgh School of Medicine, Pittsburgh, PA; Magee-Womens Research Institute, Pittsburgh, PA. Electronic address: achisx@upmc.edu.
Michele N AustinMagee-Womens Research Institute, Pittsburgh, PA.
Leslie A MeynDepartment of Obstetrics, Gynecology, and Reproductive Sciences and Center for Family Planning Research, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Felix MhlangaUniversity of Zimbabwe-University of California, San Francisco Collaborative Research Program, Harare, Zimbabwe.
Zvavahera M ChirenjeUniversity of Zimbabwe-University of California, San Francisco Collaborative Research Program, Harare, Zimbabwe.
Sharon L HillierDepartment of Obstetrics, Gynecology, and Reproductive Sciences and Center for Family Planning Research, University of Pittsburgh School of Medicine, Pittsburgh, PA; Magee-Womens Research Institute, Pittsburgh, PA.
University of Pittsburgh · USUniversity of Zimbabwe-University of California San Francisco · ZWMagee-Womens Research Institute · US

Funding

Quantification of Immune Cells in Women Using ContraceptionR01AI102835 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI ACHILLES, SHARON LYNELLE · 2012 to 2016
$2.7M
NIAID NIH HHS R01 AI102835
6 · The paper itself

Abstract

backgroundData evaluating the impact of contraceptives on the vaginal microbiome are limited and inconsistent.

objectiveWe hypothesized that women initiating copper intrauterine device use would have increased bacterial vaginosis and bacterial vaginosis-associated microbes with use compared to women initiating and using hormonal contraceptive methods. STUDY

designVaginal swabs (N = 1047 from 266 participants seeking contraception) for Nugent score determination of bacterial vaginosis and quantitative polymerase chain reaction analyses for assessment of specific microbiota were collected from asymptomatic, healthy women aged 18-35 years in Harare, Zimbabwe, who were confirmed to be free of nonstudy hormones by mass spectrometry at each visit. Contraception was initiated with an injectable (depot medroxyprogesterone acetate [n = 41], norethisterone enanthate [n = 44], or medroxyprogesterone acetate and ethinyl estradiol [n = 40]), implant (levonorgestrel [n = 45] or etonogestrel [n = 48]), or copper intrauterine device (n = 48) and repeat vaginal swabs were collected after 30, 90, and 180 days of continuous use. Self-reported condom use was similar across all arms at baseline. Quantitative polymerase chain reaction was used to detect Lactobacillus crispatus, L jensenii, L gasseri/johnsonii group, L vaginalis, L iners, Gardnerella vaginalis, Atopobium vaginae, and Megasphaera-like bacterium phylotype I from swabs. Modified Poisson regression and mixed effects linear models were used to compare marginal prevalence and mean difference in quantity (expressed as gene copies/swab) prior to and during contraceptive use.

resultsBacterial vaginosis prevalence increased in women initiating copper intrauterine devices from 27% at baseline, 35% at 30 days, 40% at 90 days, and 49% at 180 days (P = .005 compared to marginal prevalence at enrollment). Women initiating hormonal methods had no change in bacterial vaginosis prevalence over 180 days. The mean increase in Nugent score was 1.2 (95% confidence interval, 0.5-2.0; P = .001) in women using copper intrauterine devices. Although the frequency and density of beneficial lactobacilli did not change among intrauterine device users over 6 months, there was an increase in the log concentration of G vaginalis (4.7, 5.2, 5.8, 5.9; P = .046) and A vaginae (3.0, 3.8, 4.6, 5.1; P = .002) between baseline and 30, 90, and 180 days after initiation. Among other contraceptive groups, women using depot medroxyprogesterone acetate had decreased L iners (mean decrease log concentration = 0.8; 95% confidence interval, 0.3-1.5; P = .004) and there were no significant changes in beneficial Lactobacillus species over 180 days regardless of contraceptive method used.

conclusionCopper intrauterine device use may increase colonization by bacterial vaginosis-associated microbiota, resulting in increased prevalence of bacterial vaginosis. Use of most hormonal contraception does not alter vaginal microbiota.

Indexed as

Intrauterine Devices, CopperAdultContraceptive Agents, FemaleDesogestrelDNA, BacterialDrug ImplantsEthinyl EstradiolFemaleGardnerella vaginalisHumansLactobacillus crispatusLactobacillus gasseriLevonorgestrelMedroxyprogesterone AcetateMegasphaeraMicrobiotaContraceptive Agents, FemaleDesogestrelDNA, BacterialDrug ImplantsEthinyl EstradioletonogestrelLevonorgestrelMedroxyprogesterone AcetateNorethindronenorethindrone enanthatebacterial vaginosishormonal contraceptionintrauterine devicelactobacillivaginal microbiota

Identifiers

PMID29505773
PMCPMC5990849
OpenAlexW2792717467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.